In this section you will find information on Gynuity's work to develop regimens for misoprostol use for prevention and treatment of postpartum hemorrhage.

Misoprostol for Postpartum Hemorrhage
Hemorrhage is the largest single medical cause of maternal death, accounting for about one-fourth of all maternal deaths. Misoprostol has two promising ways to prevent morbidity and mortality from postpartum hemorrhage:

Misoprostol stimulates uterine contractions, which may effectively prevent or end bleeding after delivery. It may be especially important in settings where no other effective drugs are currently available for prevention or treatment of postpartum hemorrhage.

Gynuity and Family Care International have initiated a project to make misoprostol available in developing countries for prevention and treatment of postpartum hemorrhage.

Current or planned Gynuity activities in this area include: > Implementation of clinical trials to gather reliable data on misoprostol for postpartum hemorrhage prevention and treatment; > Creation of regulatory files to register misoprostol for postpartum hemorrhage indications; > Development of training and educational materials for policymakers, clinicians, and users; and > Organization of seminars, educational opportunities, and training courses to share information and stimulate interest in the drug’s potential.

Follow this link to learn more about the impact of postpartum hemorrhage on safe motherhood and details of the initiative.

IInformation about our postpartum hemorrhage trials are described in the following summaries.

>	Misoprostol for treatment of PPH
>	Misoprostol for adjunct treatment of PPH - WHO collaboration
>	Pakistan PPH treatment study
>	Pakistan PPH prevention study

Download general information on misoprostol for postpartum hemorrhage.

Other documents available on this topic include:

>	"Route of misoprostol administration"
>	"Misoprostol: An emerging technology for women's health"

Back to top